Regeneron Wins Higher Bar At Trial For FCA Kickback Theory

By Daniel Wilson · September 28, 2023, 7:30 PM EDT

A Massachusetts federal judge has ruled that the federal government must prove that alleged kickbacks by biotechnology company Regeneron related to its drug Eylea had a direct connection to false claims,...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

United States of America v. Regeneron Pharmaceuticals, Inc.

Case Number

Court

Massachusetts

Nature of Suit

Other Statutes: False Claims Act

Date Filed

June 24, 2020

Recent Articles By Daniel

November 04, 2024
VA Accused Of Choosing 'Pass-Through' Co. For $257M Deal
October 28, 2024
Gov't Says No Duty To Pay $69M In COVID Testing Claims
October 01, 2024
Novel FCA Decision Amplifies Voices Of Whistleblower Critics
September 27, 2024
Fed. Circ. Won't Revive $5.9M CMS Contingency Fee Suit
September 25, 2024
Novel Labor Clause Ruling May Beg Scrutiny In Court
September 20, 2024
Judge Says $116M CIA Deal Protest Is Pot Calling Kettle Black
September 09, 2024
House OKs Bill To Bar Contracts With Chinese Biotech Cos.
September 04, 2024
Groups Urge DC Circ. To Reject Pharma Terrorism Liability Claims
August 15, 2024
NIH Accused Of Wrongly Eliminating Cos. From $50B IT Deal
August 12, 2024
GAO Says VA Deal Awardee Wasn't Missing Key Staff Member